# Packet 01.5 — Discovery Pass 47

STATUS: DISCOVERY IN PROGRESS
PHASE: PROBLEM FINDING ONLY
ROUTING: NOT STARTED
COUNT MODE: NATURAL YIELD
DATE: 2026-06-13

This pass looks for pharmaceutical-care and medication-system failure involving prescribing, dispensing, medication reconciliation, interactions, adherence, shortages, counterfeit medicines, controlled substances, and adverse-event detection.

## Provisional records

### PRESCRIBE-001 — Medication choice is made from an incomplete patient state

Diagnosis, allergies, pregnancy, kidney or liver function, current medicines, supplements, substance use, and prior reactions may be missing or stale.

HARM: a clinically reasonable prescription becomes unsafe for the actual patient.

OVERLAP TO CHECK: MEDINT-003, DATA-001.

### PRESCRIBE-002 — Dose is copied forward after the patient or condition changes

Weight, age, organ function, severity, formulation, and treatment goal may change while the prior dose persists.

HARM: yesterday’s correct dose becomes today’s overdose or undertreatment.

OVERLAP TO CHECK: GOVREC-002, CHANGE-005.

### PRESCRIBE-003 — Clinical decision support creates false reassurance

An order may pass automated checks even when data are incomplete, rules are outdated, or the relevant interaction is not modeled.

HARM: absence of an alert is treated as evidence of safety.

OVERLAP TO CHECK: HEALTH-002, MODEL-003.

### PRESCRIBE-004 — Alert fatigue suppresses the one warning that matters

Frequent low-value warnings may train clinicians to override or ignore alerts.

HARM: a high-consequence contraindication is dismissed with routine noise.

OVERLAP TO CHECK: NOTIFY-004, DEBRIS-003.

### PRESCRIBE-005 — Off-label use is adopted faster than evidence and monitoring mature

Practice patterns, early studies, expert opinion, and market pressure may spread before risks are well characterized.

HARM: broad use outruns the evidence needed to detect harm.

OVERLAP TO CHECK: MEDINT-004, PUB-004.

### PRESCRIBE-006 — Prescribing incentive conflicts with patient need

Formulary pressure, marketing, productivity targets, reimbursement, convenience, and defensive medicine may shape choice.

HARM: medication selection reflects institutional incentives more than patient benefit.

OVERLAP TO CHECK: INCENT-001, PRICE-001.

### DISPENSE-001 — Correct medicine is dispensed to the wrong person

Similar names, identifiers, queues, labels, and pickup workflows may attach one prescription to another patient.

HARM: one patient misses therapy while another receives an unintended drug.

OVERLAP TO CHECK: BIOSEC-003, ID-002.

### DISPENSE-002 — Look-alike or sound-alike products are confused

Packaging, names, strengths, dosage forms, and storage position may be too similar.

HARM: the wrong medicine or concentration is selected despite normal workflow.

OVERLAP TO CHECK: LABEL-002, UI-003.

### DISPENSE-003 — Compounding changes concentration or contamination risk

Measurement, mixing, sterility, beyond-use date, storage, and documentation may vary from the intended preparation.

HARM: a customized medicine becomes under-strength, toxic, or contaminated.

OVERLAP TO CHECK: CONTAM-002, QUALITY-003.

### DISPENSE-004 — Counseling does not match the actual formulation

Immediate-release, extended-release, liquid, injectable, transdermal, inhaled, and device-assisted products may require different use.

HARM: the right drug is used in the wrong way.

OVERLAP TO CHECK: DOC-005, FORM-001.

### DISPENSE-005 — Delivery preserves custody but not medication condition

Heat, cold, moisture, light, delay, tampering, and failed handoff may occur after dispensing.

HARM: a correctly filled medicine reaches the patient degraded or unusable.

OVERLAP TO CHECK: COLD-001, TRACE-003.

### RECONMED-001 — Medication list contains prescriptions that the patient no longer takes

Old orders, duplicate systems, discontinued therapies, and incomplete updates may remain active in records.

HARM: clinicians act on a fictional medication regimen.

OVERLAP TO CHECK: GOVREC-001, STRUCT-006.

### RECONMED-002 — Patient-reported use is dismissed when it conflicts with the chart

Informal dosing, supplements, borrowed medicines, cost-driven changes, and side-effect avoidance may not appear in records.

HARM: the documented list overrides the patient’s actual behavior.

OVERLAP TO CHECK: HEALTH-006, FOODACCESS-003.

### RECONMED-003 — Care transition drops start, stop, or dose-change instructions

Hospital discharge, specialist referral, pharmacy transfer, home care, and long-term care may each hold part of the plan.

HARM: the patient receives duplicated, omitted, or contradictory therapy.

OVERLAP TO CHECK: HANDOFF-005, COLLAB-002.

### RECONMED-004 — Reconciliation confirms names but misses indication and duration

A list may be technically accurate while the reason, target, taper, and planned stop date are unknown.

HARM: unnecessary or harmful therapy continues indefinitely.

OVERLAP TO CHECK: EXP-006, TRACE-003.

### MEDINTX-001 — Drug interaction is missed because medicines are split across systems

Hospitals, clinics, pharmacies, specialists, telehealth, and consumer products may not share a complete list.

HARM: no single system sees the hazardous combination.

OVERLAP TO CHECK: SYNC-003, COLLAB-004.

### MEDINTX-002 — Food, supplement, alcohol, or substance interaction is omitted

Interaction checking may focus on prescription medicines while ignoring common nonprescription exposures.

HARM: the medication plan is unsafe in the patient’s real environment.

OVERLAP TO CHECK: NUTRI-005, PRESCRIBE-001.

### MEDINTX-003 — Interaction severity depends on timing and dose that the system does not model

Spacing, accumulation, half-life, intermittent use, and organ function may determine risk.

HARM: a generic interaction label either misses danger or causes unnecessary avoidance.

OVERLAP TO CHECK: TIME-001, MEAS-002.

### MEDINTX-004 — Multiple modest risks combine into one severe effect

Sedation, bleeding, blood-pressure change, rhythm effects, kidney stress, and confusion may accumulate across several medicines.

HARM: each medicine appears acceptable alone while the regimen becomes dangerous.

OVERLAP TO CHECK: INTERACT-001, CASCADE-002.

### MEDINTX-005 — Interaction database lags new evidence and new products

Recently approved drugs, reformulations, genetic findings, and post-market signals may not reach decision tools promptly.

HARM: outdated reference data silently approves a hazardous combination.

OVERLAP TO CHECK: VER-001, PHARMVIG-001.

### ADHERE-001 — Nonadherence is treated as patient refusal rather than system failure

Cost, transport, side effects, complexity, literacy, disability, culture, caregiving, and supply may prevent use.

HARM: structural barriers are misclassified as personal irresponsibility.

OVERLAP TO CHECK: NUTRI-004, ESSENTIAL-002.

### ADHERE-002 — Reminder systems encourage the wrong regimen after a medication change

Apps, pillboxes, calendars, caregiver routines, and automated messages may retain obsolete instructions.

HARM: adherence technology reliably delivers the wrong schedule.

OVERLAP TO CHECK: SCHED-007, RECONMED-001.

### ADHERE-003 — Simplifying a regimen hides clinically important timing requirements

Once-daily packaging, synchronized refills, and convenience dosing may conflict with meals, monitoring, or spacing.

HARM: improved convenience reduces effectiveness or increases harm.

OVERLAP TO CHECK: MEDINTX-003, FRAME-002.

### ADHERE-004 — Side-effect concealment preserves access or avoids blame

Patients may underreport symptoms when they fear discontinuation, stigma, cost, hospitalization, or clinician disapproval.

HARM: the treatment continues while preventable injury worsens.

OVERLAP TO CHECK: MINEWORK-001, HEALTH-006.

### SHORTMED-001 — Shortage substitution changes dose, route, monitoring, or risk

An alternative may have different concentration, formulation, device, frequency, or adverse effects.

HARM: continuity of supply is mistaken for continuity of therapy.

OVERLAP TO CHECK: COUNTERFEIT-005, CHANGE-005.

### SHORTMED-002 — Scarce medication allocation lacks transparent criteria

Age, prognosis, ability to pay, geography, institutional status, and timing may shape access.

HARM: life-affecting scarcity is resolved through hidden values.

OVERLAP TO CHECK: ALLOC-001, MEDRAD-004.

### SHORTMED-003 — Hoarding and stockpiling deepen the shortage

Institutions, distributors, clinicians, and patients may secure extra supply when scarcity is expected.

HARM: defensive purchasing accelerates unequal depletion.

OVERLAP TO CHECK: RESCON-002, PRICE-002.

### SHORTMED-004 — Shortage communication arrives after clinical plans are committed

Prescribers, pharmacies, hospitals, and patients may learn at different times.

HARM: treatment begins or changes without a viable supply path.

OVERLAP TO CHECK: COMMS-001, SUPPLY-001.

### MEDFAKE-001 — Counterfeit medicine copies packaging more convincingly than formulation

Labels, seals, tablets, and codes may appear authentic while ingredients, strength, purity, or sterility differ.

HARM: visual authenticity hides ineffective or toxic medicine.

OVERLAP TO CHECK: COUNTERFEIT-001, AUTHENT-005.

### MEDFAKE-002 — Legitimate supply chain is penetrated through emergency sourcing

Shortage, broker use, cross-border procurement, and distributor substitution may introduce unverified product.

HARM: trusted channels transmit counterfeit or diverted medicines.

OVERLAP TO CHECK: COUNTERFEIT-003, SHORTMED-001.

### MEDFAKE-003 — Online access bypasses clinical and product verification

Direct-to-consumer sellers may obscure prescriber identity, product origin, storage, and legal status.

HARM: convenience combines medical misuse with counterfeit risk.

OVERLAP TO CHECK: TERMS-001, ADS-004.

### PHARMVIG-001 — Adverse-event detection depends on voluntary reporting

Patients and clinicians may not recognize, attribute, document, or report a reaction.

HARM: rare or delayed harms remain invisible after broad use.

OVERLAP TO CHECK: INCDET-002, OBS-003.

### PHARMVIG-002 — Common background symptoms hide a medication signal

Fatigue, falls, confusion, pain, nausea, and mood changes may be attributed to age or disease.

HARM: treatment injury is normalized as the patient’s condition.

OVERLAP TO CHECK: MEDINT-002, HEALTH-001.

### PHARMVIG-003 — Post-market evidence is biased toward well-connected populations

Insurance claims, digital records, specialty centers, and reporting systems may underrepresent marginalized groups.

HARM: safety conclusions do not reflect everyone using the medicine.

OVERLAP TO CHECK: GENOME-002, DESIGN-004.

### PHARMVIG-004 — Safety warning changes behavior without measuring replacement harm

Restricting one medicine may shift patients to untreated disease, unsafe alternatives, illicit supply, or abrupt withdrawal.

HARM: risk reduction in one pathway creates injury in another.

OVERLAP TO CHECK: CONTAIN-001, SHORTMED-001.

### CONTROLLED-001 — Misuse prevention blocks legitimate pain or addiction treatment

Rigid thresholds, surveillance, stigma, and fear of enforcement may deter appropriate care.

HARM: population-level control produces undertreatment and unsafe substitution.

OVERLAP TO CHECK: POLICE-003, PHARMVIG-004.

### CONTROLLED-002 — Diversion monitoring mistakes unusual need for wrongdoing

High dose, multiple prescribers, early refill, travel, disability, or complex illness may trigger suspicion.

HARM: vulnerable patients lose care because risk signals lack context.

OVERLAP TO CHECK: FRAUD-002, FRAME-003.

### CONTROLLED-003 — Abrupt policy or supply change creates withdrawal and illicit-market risk

Coverage limits, pharmacy refusal, prescriber departure, shortage, or enforcement change may stop access suddenly.

HARM: a control intervention creates immediate medical and public-safety danger.

OVERLAP TO CHECK: SHORTMED-004, CRISIS-003.

## Pass 47 result

Natural-yield provisional records: 38
Routing decisions made: 0
Records closed: 0
Deduplication required later: Yes
Discovery saturation: NOT REACHED

Corrected working total:
- Preserved baseline: 122
- Prior actual provisional headings: 1835
- Pass 47 natural-yield provisional: 38
- Current actual provisional headings: 1873
- Current combined working total: 1995

NEXT DISCOVERY PASS:
Population-scale public health and pandemic systems, including surveillance, case definitions, laboratory networks, vaccination, isolation, public communication, supply allocation, health-system capacity, and cross-border coordination.

END PACKET 01.5 — DISCOVERY PASS 47
